Page 791 - Withrow and MacEwen's Small Animal Clinical Oncology, 6th Edition

CHAPTER 33 Hematopoietic Tumors 769

731. Tasca S, Carli E, Caldin M, et al.: Hematologic abnormalities and flow 754. Jacobs A: Treatment for the myelodysplastic syndromes, Haemato-
cytometric immunophenotyping results in dogs with hematopoietic logica 72:477–480, 1987.
neoplasia: 210 cases (2002-2006), Vet Clin Pathol 38:2–12, 2009. 755. Kelsey SM, Newland AC, Cunningham J, et al.: Sustained hae-
VetBooks.ir 732. Villiers E, Baines S, Law AM, et al.: Identification of acute myeloid matological response to high-dose oral alfacalcidol in patients with
leukemia in dogs using flow cytometry with myeloperoxidase,
myelodysplastic syndromes, Lancet 340:316–317, 1992.
MAC387, and a canine neutrophil-specific antibody, Vet Clin
Pathol 35:55–71, 2006. 756. Ohno R, Naoe T, Hirano M, et al.: Treatment of myelodysplastic
syndromes with all-trans retinoic acid. Leukemia Study Group of
733. Peterson ME, Zanjani ED: Inappropriate erythropoietin produc- the Ministry of Health and Welfare, Blood 81:1152–1154, 1993.
tion from a renal carcinoma in a dog with polycythemia, J Am Vet 757. Matus RE, Leifer CE, MacEwen EG, et al.: Prognostic factors for
Med Assoc 179:995–996, 1981. multiple myeloma in the dog, J Am Vet Med Assoc 188:1288–1292,
734. Scott RCPA: Renal carcinoma associated with secondary polycy- 1986.
themia in a dog, J Am Anim Hosp Assoc 8:275–283, 1972. 758. Liu S, Dorfman HD, Hurvitz AI, et al.: Primary and secondary
735. Waters DJPJ: Secondary polycythemia associated with renal disease bone tumors in the dog, J Small Anim Pract 18:313–326, 1977.
in the dog: two case reports and review of literature, J Am Anim 759. Weiss DJ: A retrospective study of the incidence and the classifica-
Hosp Assoc 24:109–114, 1988. tion of bone marrow disorders in the dog at a veterinary teaching
736. Cook SM, Lothrop Jr CD: Serum erythropoietin concentrations hospital (1996-2004), J Vet Intern Med 20:955–961, 2006.
measured by radioimmunoassay in normal, polycythemic, and ane- 760. Tappin SW, Taylor SS, Tasker S, et al.: Serum protein electrophore-
mic dogs and cats, J Vet Intern Med 8:18–25, 1994. sis in 147 dogs, Vet Rec 168:456, 2011.
737. Giger U: Serum erythropoietin concentrations in polycythemic and 761. Fernandez R, Chon E: Comparison of two melphalan protocols
anemic dogs, Proc 9th Annual Vet Med Forum (ACVIM) 143–145, and evaluation of outcome and prognostic factors in multiple
1991. myeloma in dogs, J Vet Intern Med 32:1060–1069, 2018.
738. Reimann KA, Knowlen GG, Tvedten HW: Factitious hyperkale- 762. Thamm DH, Vail DM, Kurzman ID, et al.: GS–9219/VDC-
mia in dogs with thrombocytosis. The effect of platelets on serum 1101-a prodrug of the acyclic nucleotide PMEG has antitumor
potassium concentration, J Vet Intern Med 3:47–52, 1989. activity in spontaneous canine multiple myeloma, BMC Vet Res
739. Weiss DJ, Aird B: Cytologic evaluation of primary and secondary 10(30), 2014.
myelodysplastic syndromes in the dog, Vet Clin Pathol 30:67–75, 763. Osborne CA, Perman V, Sautter JH, et al.: Multiple myeloma in
2001. the dog, J Am Vet Med Assoc 153:1300–1319, 1968.
740. Friedrichs KRYK: How to collect diagnostic bone marrow samples, 764. MacEwen EG, Hurvitz AI: Diagnosis and management of mono-
Vet Med 8:578–588, 2005. clonal gammopathies, Vet Clin North Am 7:119–132, 1977.
741. Feeney DA, Sharkey LC, Steward SM, et al.: Applicability of 3T 765. Carpenter J, Andrews LK, Holzworth J: Tumors and tumor like
body MRI in assessment of nonfocal bone marrow involvement of lesions. In Holzworth J, editor: Diseases of the cat: medicine and
hematopoietic neoplasia in dogs, J Vet Intern Med 27:1165–1171, surgery, Philadelphia, 1987, WB Saunders.
2013. 766. Engle G, Brodey RS: A retrospective study of 395 feline neoplasms,
742. Feeney DA, Sharkey LC, Steward SM, et al.: Parenchymal signal J Am Anim Hosp Assoc 5:21–31, 1969.
intensity in 3-T body MRI of dogs with hematopoietic neoplasia, 767. Patel RT, Caceres A, French AF, et al.: Multiple myeloma in 16 cats:
Comp Med 63:174–182, 2013. a retrospective study, Vet Clin Pathol 34:341–352, 2005.
743. Schmidt JM, North SM, Freeman KP, et al.: Feline paediatric 768. Taylor SS, Tappin SW, Dodkin SJ, et al.: Serum protein electropho-
oncology: retrospective assessment of 233 tumours from cats up to resis in 155 cats, J Feline Med Surg 12:643–653, 2010.
one year (1993 to 2008), J Small Anim Pract 51:306–311, 2010. 769. Cannon CM, Knudson C, Borgatti A: Clinical signs, treatment,
744. Gorman NT, Evans RJ: Myeloproliferative disease in the dog and outcome in cats with myeloma–related disorder receiving sys-
and cat: clinical presentations, diagnosis and treatment, Vet Rec temic therapy, J Am Anim Hosp Assoc 51:239–248, 2015.
121:490–496, 1987. 770. Hanna F: Multiple myelomas in cats, J Feline Med Surg 7:275–287,
745. Hamlin RH, Duncan RC: Acute nonlymphocytic leukemia in a 2005.
dog, J Am Vet Med Assoc 196:110–112, 1990. 771. Mellor PJ, Haugland S, Murphy S, et al.: Myeloma-related dis-
746. Theilen GH MB, Gardner MB: Hematopoietic neoplasms, sarco- orders in cats commonly present as extramedullary neoplasms in
mas and related conditions. In Theilen GH, Madewell, editors: Vet- contrast to myeloma in human patients: 24 cases with clinical fol-
erinary cancer medicine, ed 2, Philadelphia, 1987, Lea & Febiger. low-up, J Vet Intern Med 20:1376–1383, 2006.
747. Lawless S, McMullin MF, Cuthbert R, et al.: (32)P in the treatment 772. Qurollo BA, Balakrishnan N, Cannon CZ, et al.: Co-infection
of myeloproliferative disorders, Ulster Med J 85:83–85, 2016. with Anaplasma platys, Bartonella henselae, Bartonella koehlerae
748. Smith M, Turrel JM: Radiophosphorus (32P) treatment of bone and ‘Candidatus Mycoplasma haemominutum’ in a cat diagnosed
marrow disorders in dogs: 11 cases (1970-1987), J Am Vet Med with splenic plasmacytosis and multiple myeloma, J Feline Med
Assoc 194:98–102, 1989. Surg 16:713–720, 2014.
749. Lyss AP: Enzymes and random synthetics. In Perry MC, editor: The 773. Geigy C, Riond B, Bley CR, et al.: Multiple myeloma in a dog with
chemotherapy source book, Baltimore, 1992, Williams & Wilkins, pp multiple concurrent infectious diseases and persistent polyclonal
398–412. gammopathy, Vet Clin Pathol 42:47–54, 2013.
750. Bolin RW, Robinson WA, Sutherland J, et al.: Busulfan versus 774. Cangul IT, Wijnen M, Van Garderen E, et al.: Clinico–pathologi-
hydroxyurea in long-term therapy of chronic myelogenous leuke- cal aspects of canine cutaneous and mucocutaneous plasmacyto-
mia, Cancer 50:1683–1686, 1982. mas, J Vet Med A Physiol Pathol Clin Med 49:307–312, 2002.
751. Rosenthal S, Canellos GP, Whang-Peng J, et al.: Blast crisis of 775. Imahori S, Moore GE: Multiple myeloma and prolonged stimula-
chronic granulocytic leukemia. Morphologic variants and thera- tion of reticuloendothelial system, N Y State J Med 72:1625–1628,
peutic implications, Am J Med 63:542–547, 1977. 1972.
752. Ganser A, Hoelzer D: Treatment of myelodysplastic syndromes 776. London CA, Hannah AL, Zadovoskaya R, et al.: Phase I dose-esca-
with hematopoietic growth factors, Hematol Oncol Clin North Am lating study of SU11654, a small molecule receptor tyrosine kinase
6:633–653, 1992. inhibitor, in dogs with spontaneous malignancies, Clin Cancer Res
753. Liesveld JL, Lichtman MA: Myelodysplastic syndromes (clonal 9:2755–2768, 2003.
cytopenias and oligoblastic myelogenous leukemia). In Lichtman 777. Porter DD, Dixon FJ, Larsen AE: The development of a myeloma-
MA, Kaushansky K, Seligsohn U, et al.: Williams hematology, ed 8, like condition in mink with Aleutian disease, Blood 25:736–742,
New York, 2010, McGraw-Hill. 1965.